Latha Vairavan
SVP Chief Financial Officer · Arcutis Biotherapeutics, Inc.
- 2025
- May 13, 2026
- 6
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Latha Vairavan files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Todd Watanabe - $4.44M in ARQT purchases and sales in the last 12 months
- Masaru Matsuda - $2.21M in ARQT purchases and sales in the last 12 months
- Howard G. Welgus - $1.95M in ARQT purchases and sales in the last 12 months
- Patrick Burnett - $1.56M in ARQT purchases and sales in the last 12 months
- Keith R. Leonard - $997K in ARQT purchases and sales in the last 12 months
- Terrie Curran - $984K in ARQT purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Latha Vairavan?
Latha Vairavan is a corporate insider, tracked as SVP Chief Financial Officer of Arcutis Biotherapeutics, Inc. (ARQT). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Latha Vairavan last file a Form 4?
The most recent primary Form 4 on record is dated 13 May 2026, one of 6 filings going back to 2025.
Has Latha Vairavan been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($150K) across all tracked filings.
